Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 51655-747

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 51655-747). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 747 52 Master Bottle Label Approval Rev A 07 21)

Label (51655 747 52 Master Bottle Label Approval   Rev A 07 21)
This is a product information sheet for Atorvastatin Calcium tablets, USP 80mg. The tablets come in a package of 30 and require a prescription. The package insert should be consulted for dosage instructions. The tablets should be stored in the original container at a controlled room temperature and kept out of reach of children. The product is repackaged by Northwind Pharmaceuticals. The tablets contain Atorvastatin and Calcium, with a total of 80mg Atorvastatin, and are manufactured by Ascend Laboratories. Lot and expirations numbers are provided.*
FDA Label Image

Atorvastatin-fig-1 (Atorvastatin Fig 1)

Atorvastatin-fig-1 (Atorvastatin Fig 1)
This appears to be a graph or chart showing cumulative incidence over time, with the percentage ranging from 0-40%. The data seems to be comparing the effectiveness of Atorastatn versus a placebo, with an HR (Hazard Ratio) of 0.64 and a significant p-value of 0.0005. The graph spans a time period of 20-35 years.*
FDA Label Image

Atorvastatin-fig-2 (Atorvastatin Fig 2)

Atorvastatin-fig-2 (Atorvastatin Fig 2)
This is a graphical representation showing the cumulative hazard percentages for a placebo group and a group taking Atorvastatin. The hazard ratio of Atorvastatin compared to placebo was 0.63 (p=0.001) over four years of follow-up. The x-axis represents the time to the first primary endpoint in years.*
FDA Label Image

Atorvastatin-fig-3 (Atorvastatin Fig 3)

FDA Label Image

Atorvastatin-st (Atorvastatin St)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.